These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23840706)

  • 1. Targeting Leishmania major Antigens to Dendritic Cells In Vivo Induces Protective Immunity.
    Matos I; Mizenina O; Lubkin A; Steinman RM; Idoyaga J
    PLoS One; 2013; 8(6):e67453. PubMed ID: 23840706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.
    Kronenberg K; Brosch S; Butsch F; Tada Y; Shibagaki N; Udey MC; von Stebut E
    J Invest Dermatol; 2010 Nov; 130(11):2602-10. PubMed ID: 20574442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens.
    Berberich C; Ramírez-Pineda JR; Hambrecht C; Alber G; Skeiky YA; Moll H
    J Immunol; 2003 Mar; 170(6):3171-9. PubMed ID: 12626575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis.
    von Stebut E; Belkaid Y; Nguyen BV; Cushing M; Sacks DL; Udey MC
    Eur J Immunol; 2000 Dec; 30(12):3498-506. PubMed ID: 11093169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dectin-1 Positive Dendritic Cells Expand after Infection with
    Zimara N; Chanyalew M; Aseffa A; van Zandbergen G; Lepenies B; Schmid M; Weiss R; Rascle A; Wege AK; Jantsch J; Schatz V; Brown GD; Ritter U
    Front Immunol; 2018; 9():263. PubMed ID: 29535708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacterial lipoprotein-based vaccines induce tumor necrosis factor-dependent type 1 protective immunity against Leishmania major.
    Cote-Sierra J; Bredan A; Toldos CM; Stijlemans B; Brys L; Cornelis P; Segovia M; de Baetselier P; Revets H
    Infect Immun; 2002 Jan; 70(1):240-8. PubMed ID: 11748189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Assessment of Induced Immune Responses Following Intramuscular Immunization with Fusion and Cocktail of LeIF, LACK and TSA Genes Against Cutaneous Leishmaniasis in BALB/c Mice.
    Maspi N; Ghaffarifar F; Sharifi Z; Dalimi A; Dayer MS
    Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):55-64. PubMed ID: 28779346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.
    Coler RN; Skeiky YA; Bernards K; Greeson K; Carter D; Cornellison CD; Modabber F; Campos-Neto A; Reed SG
    Infect Immun; 2002 Aug; 70(8):4215-25. PubMed ID: 12117930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major.
    Soussi N; Milon G; Colle JH; Mougneau E; Glaichenhaus N; Goossens PL
    Infect Immun; 2000 Mar; 68(3):1498-506. PubMed ID: 10678966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirements for Th1-dependent immunity against infection with Leishmania major.
    von Stebut E; Udey MC
    Microbes Infect; 2004 Oct; 6(12):1102-9. PubMed ID: 15380780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis.
    Walker PS; Scharton-Kersten T; Rowton ED; Hengge U; Bouloc A; Udey MC; Vogel JC
    Hum Gene Ther; 1998 Sep; 9(13):1899-907. PubMed ID: 9741428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
    Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
    J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge.
    Lakhal-Naouar I; Koles N; Rao M; Morrison EB; Childs JM; Alving CR; Aronson NE
    Vaccine; 2019 Jan; 37(3):516-523. PubMed ID: 30528328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers.
    Iborra S; Abánades DR; Parody N; Carrión J; Risueño RM; Pineda MA; Bonay P; Alonso C; Soto M
    Clin Exp Immunol; 2007 Nov; 150(2):375-85. PubMed ID: 17900304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major.
    Gurunathan S; Sacks DL; Brown DR; Reiner SL; Charest H; Glaichenhaus N; Seder RA
    J Exp Med; 1997 Oct; 186(7):1137-47. PubMed ID: 9314562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.
    Ramírez-Pineda JR; Fröhlich A; Berberich C; Moll H
    J Immunol; 2004 May; 172(10):6281-9. PubMed ID: 15128817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice.
    Shah JA; Darrah PA; Ambrozak DR; Turon TN; Mendez S; Kirman J; Wu CY; Glaichenhaus N; Seder RA
    J Exp Med; 2003 Jul; 198(2):281-91. PubMed ID: 12874261
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A subset of dendritic cells induces CD4+ T cells to produce IFN-gamma by an IL-12-independent but CD70-dependent mechanism in vivo.
    Soares H; Waechter H; Glaichenhaus N; Mougneau E; Yagita H; Mizenina O; Dudziak D; Nussenzweig MC; Steinman RM
    J Exp Med; 2007 May; 204(5):1095-106. PubMed ID: 17438065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice.
    Biedermann T; Zimmermann S; Himmelrich H; Gumy A; Egeter O; Sakrauski AK; Seegmüller I; Voigt H; Launois P; Levine AD; Wagner H; Heeg K; Louis JA; Röcken M
    Nat Immunol; 2001 Nov; 2(11):1054-60. PubMed ID: 11600887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.